The Newswire

Your daily serving of financial goodness

Neurotech IPO Offers Access to the Growing Medical Device Industry

Neurotech IPO Offers Access to the Growing Medical Device Industry
'Mente' is a wearable medical device which assists in managing the symptoms of autism in children.
Oct 10, 2016 By Simon Herrmann Tags: IPO, NTI

Neurotech International seeks to raise $7 million to list on the ASX on 17 October 2016. Neurotech aims to address the growing medical device industry but is the IPO a suitable opportunity for Australian investors?

It is estimated that 1 in 68 children is affected by autism and to date the condition has no known cure. Autism affects the way individuals behave in social interactions as well as their ability to learn and communicate. The goal of medical treatments is to reduce symptoms to improve the lifestyle and lower the risk of additional development delays.

Neurotech International is a neuroscience focused technology company which aims to commercialise its ‘Mente Autism’ technology. Mente is a wearable medical device which assists in managing the symptoms of autism in children. The neuro-device market is one of the fastest growing sectors in the medical device industry and is expected to reach US$13.9 billion in revenue by 2019.

The company aims to raise $7million in a conventional IPO to fund development and research for its technology and accelerate sales and marketing efforts. Neurotech’s predecessor product has already had initial sales across Europe, Middle East and Asia with approximately 350 units being sold to date. The company has executed an initial distribution agreement to sell a minimum of 8,700 units via a distribution partner in Italy over the next three years. While the company is not expected to reach profitability in the short-term, the agreement provides the company with a near-term revenue opportunity. In mid 2017, results from the U.S. Clinical Trials are expected, which would be a major validation signal for the company and could assist Neurotech to apply for FDA clearance and enter the large U.S. market.

However, the Mente technology remains to be validated in a commercial setting and there is no guarantee that the company will be able to commercialise its product and reach profitability. With only one material contract in place, termination of the agreement would adversely impact Neurotech’s financial performance. Other hurdles include reliance on external capital and lack of patents.

The IPO is speculative but the upcoming clinical trial in the U.S. could be a near-term catalyst and significantly enhance the profile of Neurotech if successful.

Shares on Offer: 35m
Listing Price: $0.20
Market Capitalisation: 17.6m
Listing Date: October 17

This article was published first in The Australian.

Share this article

Simon Herrmann Author: Simon Herrmann Oct 10, 2016

Simon is a financial analyst at independent research firm Wise-owl specialised in small-mid cap growth opportunities and ethical investment opportunities. Simon's aim is to disrupt the cliché approach to investment decision making as he believes that socially and environmentally responsible behaviour is a necessity to long-term wealth creation. Simon has a deep fundamental understanding of the global financial landscape and has compiled 300+ research reports, valuations and corporate appraisals. Simon is commonly featured in major media outlets and his research is published weekly in The Australian.

Interested in IPOs? Bid directly here:

Disclaimer: Clicking on this link will take you to a third-party website. We do not control or give advice regarding the content or links that appear on these sites and Wise-owl accepts no responsibility or liability in respect of any third party materials. Wise-owl may earn a commission from any product or service from third party websites.

Amaero eyes US defence market with 3D printing technology

The 3D printing process builds a three-dimensional object from a computer-aided design model, usually by successively adding material layer by layer, which is why it is also called additive manufacturing.

Author: Simon Herrmann Nov 21, 2019


Sign Up for Free Trial
Recent Tweets
Recent News